Skip to main content

Epidiolex Side Effects

Generic name: cannabidiol

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 30, 2024.

Note: This document provides detailed information about Epidiolex Side Effects associated with cannabidiol. Some dosage forms listed on this page may not apply specifically to the brand name Epidiolex.

Applies to cannabidiol: oral solution.

Serious side effects of Epidiolex

Along with its needed effects, cannabidiol (the active ingredient contained in Epidiolex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking cannabidiol:

More common side effects

  • agitation
  • chest pain
  • chills
  • cough
  • dark urine
  • fever
  • hoarseness
  • irritability
  • loss of appetite
  • right upper quadrant abdominal pain
  • nausea
  • painful or difficult urination
  • pain or tenderness in the upper stomach
  • pale stools
  • sore throat
  • trouble breathing
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • vomiting
  • yellow eyes or skin

Less common side effects

  • aggression
  • anger
  • blue lips, fingernails, or skin
  • confusion
  • diarrhea
  • dizziness
  • fast heartbeat
  • irregular, fast or slow, or shallow breathing
  • stomach pain

Other side effects of Epidiolex

Some side effects of cannabidiol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

  • lack or loss of strength
  • rash
  • trouble sleeping

Less common side effects

  • change in walking and balance
  • clumsiness or unsteadiness
  • decreased weight
  • drooling
  • increased saliva

Managing side effects (general information)

For healthcare professionals

Applies to cannabidiol: oral liquid.

General adverse events

The more commonly reported adverse reactions have included somnolence, decreased appetite, diarrhea, transaminase elevations, rash, and insomnia.[Ref]

Hepatic

In clinical trials, 13% (10 and 20 mg/kg/day) and 12% (25 mg/kg/day) of drug-treated patients experienced hepatic transaminase elevations of greater than 3 times the upper limit of normal (3 x ULN) compared to 1% in placebo patients. Less than 1% had elevations greater than 20 x ULN. In clinical trials with doses of 10 and 20 mg/kg/day, ALT elevations greater than 3 x ULN occurred in 30% of patients taking both concomitant valproate and clobazam; 21% taking concomitant valproate; 4% concomitant clobazam and 3% taking neither valproate or clobazam. With doses of 25 mg/kg/day, ALT elevations of 3 x ULN occurred in 20% of patients taking both concomitant valproate and clobazam; 25% taking concomitant valproate; 0% concomitant clobazam and 6% taking neither valproate or clobazam.

Transaminase elevations were generally dose related. ALT elevations greater than 3 x ULN occurred in 17% of patients taking 10 or 20 mg/kg/day and 12% taking 20 or 25 mg/kg/day, compared to 1% in patients taking 10 mg/kg/day.

Patients with baseline transaminase elevations above the ULN had higher rates of treatment emergent ALT elevations. For patients taking 20 mg/kg/day, ALT elevations to greater than 3 x ULN occurred in 30% of patients who had baseline ALT elevations compared to 12% in patients whose ALT levels were within the normal range at baseline.

Psychiatric

Nervous system

Somnolence and sedation (including lethargy) occurred in 32% of patients compared with 11% of those on placebo. Occurrences were higher among patients on higher doses (34% vs 27% for doses of 20 mg/kg/day and 10 mg/kg/day, respectively). Occurrences were even higher in patients on concomitant clobazam (46% vs 16%).[Ref]

Hypersensitivity

Metabolic

Hematologic

In clinical trials among patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), mean decreases in hemoglobin (0.42 g/dL) and hematocrit of (1.5%) occurred in patients receiving this drug (compared with -0.03 g/dL and -0.4%, respectively in placebo). Among patients treated for tuberous sclerosis complex (TSC), a mean decrease in hemoglobin of 0.37 g/dL (compared to 0.07 g/dL in placebo) and drop in hematocrit of 1.2% (compared to 0.2% for placebo). A new laboratory-defined anemia defined as a normal hemoglobin at baseline and a reported value less than the lower limit of normal at a subsequent time occurred in 30% of patients in the LGS and DS trials (placebo=13%) and 38% of patients in the TSC trials (placebo=15%).[Ref]

Immunologic

Respiratory

Other

Renal

Increased serum creatinine has been observed with use of this drug in healthy adults, in patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The mechanism has not been determined. An increase of about 10% has been observed within 2 weeks of initiating therapy. In healthy adults, this increase was reversible. Reversibility was not assessed in patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.[Ref]

Dermatologic

Gastrointestinal

Genitourinary

References

1. (2018) "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC

Frequently asked questions

Further information

Epidiolex side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer